The Government of Uganda has announced that it will receive more than 94,000 doses of Lenacapavir (Yeztugo), a long-acting injectable drug used to prevent HIV infection. The medication is administered twice a year.
Lenacapavir (Yeztugo) was developed by Gilead Sciences, a United States–based pharmaceutical company known for producing vaccines and antiviral medicines. Clinical trials conducted in different countries on three separate occasions showed that the drug provides 99.9% protection against HIV when taken once every six months.
On February 20, 2026, the Government of Uganda announced that it will receive 94,560 doses next week as part of expanding its national strategy to combat HIV/AIDS.
Meanwhile, Kenya recently confirmed that it received 21,000 doses of the same drug on February 17.
In July 2025, the World Health Organization (WHO) approved Lenacapavir for use. The drug is considered a major advancement because, unlike existing prevention methods that require taking pills within 72 hours after unprotected sexual contact (post-exposure prophylaxis), this injectable treatment is administered only once every six months. Another available injectable option is given every two months.
Post a Comment